β-Adrenergics enhance brain extraction of levodopa

Movement Disorders

Volumn 17, Issue 1, 2002, Pages 54-59

  Uc, Ergun Y ^a,b   Dienel, Gerald A ^a   Cruz, Nancy F ^a   Harik, Sami I ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

adrenergic receptors; Blood to brain transport; L dopa; Large neutral amino acids; Parkinson's disease

Indexed keywords

AMINO ACID; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CARBON 14; CLENBUTEROL; INDICATOR; ISOPRENALINE; ISOTOPE; LEUCINE; LEVODOPA; NADOLOL; NICOTINE; SODIUM CHLORIDE; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; BRAIN REGION; CONSCIOUSNESS; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DRUG BRAIN LEVEL; DRUG INHIBITION; DRUG ISOLATION; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG TRANSPORT; FRACTIONATION; MALE; MONKEY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; REVIEW; SYMPTOM;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTIPARKINSON AGENTS; BLOOD-BRAIN BARRIER; BRAIN; CEREBROVASCULAR CIRCULATION; LEVODOPA; MALE; PARKINSON DISEASE; RATS; RATS, WISTAR;

EID: 0036460968     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10002     Document Type: Review

References (40)

1. Lang AE, Lozano AM. Parkinson's disease. N Engl J Med 1998; 339:1130-1143.
2. Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL. The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med 1984;310:483-488.
3. Fabbrini G, Juncos J, Mouradian MM, Serrati C, Chase TN. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol 1987;21:370-376.
4. Eriksson T, Granerus AK, Linde A, Carlsson A. 'On-off' phenomenon in Parkinson's disease: relationship between dopa and other large neutral amino acids in plasma. Neurology 1988;38:1245-1248.
5. Eriksson T, Carlsson A. Beta-adrenergic control of brain uptake of large neutral amino acids. Life Sci 1988;42:1583-1589.
6. Takao Y, Kamisaki Y, Itoh T. Beta-adrenergic regulation of amine precursor amino acid transport across the blood-brain barrier. Eur J Pharmacol 1992;215:245-251.
7. Alexander GM, Schwartzman RJ, Grothusen JR, Gordon SW. Effect of plasma levels of large neutral amino acids and degree of parkinsonism on the blood-to-brain transport of levodopa-in naïve and MPTP parkinsonian monkeys. Neurology 1994;44:1491-1499.
8. Alexander GM, Schwartzman RJ, Nukes TA, Grothusen JR, Hooker MD. Beta 2-adrenergic agonist as adjunct therapy to levodopa in Parkinson's disease. Neurology 1994;44:1511-1513.
9. Hishida R, Kurahashi K, Narita S, Baloa T, Matsunaga M. "Wearing-off" and β2-adrenoceptor agonist in Parkinson's disease. Lancet 1992;339:870.
10. Edwards DJ, Sorisio DA, Knopf S. Effects of the beta 2-adrenoceptor agonist clenbuterol on tyrosine and tryptophan in plasma and brain of the rat. Biochern Pharmacol 1989;38:2957-2965.
11. Uc EY, Tallent MW, Dienel GA, Cruz NF, Harik SI. Beta-adrenergic receptor agonists increase amino acid transport at the blood-brain barrier. Neurology 1999;52(6 Suppl 2):A347-A348.
12. Slocum R, Cummings JG. Amino acid analysis of physiologic samples. In: Hommes F, editor. Techniques in diagnostic human biochemical genetics: a laboratory manual. New York: Wiley-Liss; 1991. p 87-126.
13. LaManna JC, Harik SI. Regional studies of blood-brain barrier transport of glucose and leucine in awake and anesthetized rats. J Cereb Blood Flow Metab 1986;6:717-723.
14. Ohno K, Pettigrew KD, Rapoport SI. Local cerebral blood flow in the conscious rat as measured with 14C-antipyrine, 14C-iodoantipyrine and 3H-nicotine. Stroke 1979;10:62-67.
15. Hoffman BB, Lefkowitz RJ. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, editors. Goodman & Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill; 1996. p 199-248.
16. 2-Rezeptoren. Arzneimittelforschung 1976;26:1404-1420.
17. Dunnett CW. New tables for multiple comparisons with a control, Biometrics 1964;20:482-491.
18. Paetsch PR, Greenshaw AJ. Beta-adrenergic effects on plasma and brain large neutral amino acids are unaltered by chronic administration of antidepressants. J Neurochem 1991;56:2027-2032.
19. Laterra J, Keep RF, Betz AL, Goldstein GW. Blood-brain-cerebrospinal fluid barriers. In: Siegel JS, Agranoff BW, Albers RW, Fisher SK, Uhler MD, editors. Basic neurochemistry, 6th ed. Philadelphia: Lippincott-Raven; 1999. p 671-689.
20. Davis DH, Sundt TM Jr. Relationship of cerebral blood flow to cardiac output, mean arterial pressure, blood volume, and alpha and beta blockade in cats. J Neurosurg 1980;52:745-754.
21. Harik SI. Neurotransmitters and brain microvessels: biochemical and pharmacological relations. In: Seylaz J, Sarcombe R, editors. Neurotransmission and cerebrovascular function II. Amsterdam: Elsevier; 1989. p 21-31.
22. Kraenzlin ME, Keller U, Keller A, Thelin A, Arnaud MJ, Stauffacher W. Elevation of plasma epinephrine concentrations inhibits proteolysis and leucine oxidation in man via beta-adrenergic mechanisms. J Clin Invest 1989,84:388-393.
23. Ratheiser KM, Pesola GR, Campbell RG, Matthews DE. Epinephrine transiently increases amino acid disappearance to lower amino acid levels in humans. JPEN J Parenter Enteral Nutr 1999;23:279-287.
24. Miles JM, Nissen SL, Gerich JE, Haymond MW. Effects of epinephrine infusion on leucine and alanine kinetics in humans. Am J Physiol 1984;247:E166-E172.
25. Matthews DE, Pesola G, Campbell RG. Effect of epinephrine on amino acid and energy metabolism in humans. Am J Physiol 1990; 258:E948-E956.
26. Shamoon H, Jadde R, Sherwin RS. Epinephrine induced hypoamino-acidemia in normal and diabetic human subjects. Diabetes 1980;29:875-881.
27. Smith QR, Momma S, Aoyagi M, Rapoport SI. Kinetics of neutral amino acid transport across the blood-brain barrier. J Neurochem 1987;49:1651-1658.
28. Miller LP, Pardridge WM, Braun LD, Oldendorf WH. Kinetic constants for blood-brain barrier amino acid transport in conscious rats. J Neurochem 1985;45:1427-1432.
29. Sage JI, van Uitert RL, Duffy TE. Simultaneous measurement of cerebral blood flow and unidirectional movement of substances across the blood-brain barrier: theory, method, and application to leucine. J Neurochem 1981;36:1731-1738.
30. Harik SI, Sharma VK, Wetherbee JR, Warren RH, Banerjee SP. Adrenergic receptors of cerebral microvessels. Eur J Pharmacol 1980;61:207-208.
31. Harik SI, Sharma VK, Wetherbee JR, Warren RH, Banerjee SP, Adrenergic and cholinergic receptors of cerebral microvessels. J Cereb Blood Flow Metab 1981;1:329-338.
32. Kobayashi H, Maoret T, Ferrante M, Spano P, Trabucchi M. Subtypes of beta-adrenergic receptors in rat cerebral microvessels. Brain Res 1981;220:194-198.
33. Kalaria RN, Stockmeier CA, Harik SI. Brain microvessels are innervated by locus ceruleus noradrenergic neurons. Neurosci Lett 1989;97:203-208.
34. Pardridge WM, Oldendorf WH. Kinetic analysis of blood-brain barrier transport of amino acids. Biochim Biophys Acta 1975;401: 128-136.
35. Nutt JG, Woodward WR. Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 1986;36:739-744.
36. Pardridge WM. Kinetics of competitive inhibition of neutral amino acid transport across the blood-brain barrier. J Neurochem 1977; 28:103-108.
37. Pincus JH, Barry KM. Plasma levels of amino acids correlate with motor fluctuations in parkinsonism. Arch Neurol 1987;44:1006-1009.
38. Carter WJ, Lynch ME. Comparison of the effects of salbutamol and clenbuterol on skeletal muscle mass and carcass composition in senescent rats. Metabolism 1994;43:1119-1125.
39. Caruso JF, Signorile JF, Perry AC, et al. The effects of albuterol and isokinetic exercise on the quadriceps muscle group. Med Sci Sports Exerc 1995;27:1471-1476.
40. Martineau L, Horan MA, Rothwell NJ, Little RA. Salbutamol, a beta 2-adrenoceptor agonist, increases skeletal muscle strength in young men. Clin Sci 1992;83:615-621.